

Attorney Docket 036870-5073-02
U.S. Application 10/772,437
Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please amend claims 37, 41, 42 and 44 as follows:

Please cancel claim 39 without prejudice or disclaimer

Claims 1 to 36 (cancelled)

37. (currently amended) A method of treating ~~a condition associated with~~ atopic allergy or asthma in a patient comprising administering to the patient in need of treatment an effective amount of an antibody which binds to an ICACC-1 (SEQ ID NO: 6) protein.

38 to 40. (cancelled)

41. (currently amended) The method according to claim 37, wherein the [[agent]] antibody causes a decrease in bronchial hyperresponsiveness.

42. (currently amended) The method according to claim 37, wherein the [[agent]] antibody causes a decrease in inflammatory cells in the airways of the patient.

43. (previously presented) The method according to claim 42, wherein the cells are selected from the group consisting of mast cells, eosinophils, lymphocytes and epithelial cells.

44. (currently amended) The method according to claim 37, wherein the [[agent]] antibody causes an improvement in pulmonary function.

45 to 51. (cancelled)

52. (previously presented) The method according to claim 37, wherein the antibody is monoclonal.

53 to 54. (cancelled)

55. (previously presented) The method according to claim 37, wherein the antibody is administered by inhalation.

Attorney Docket 036870-5073-02
U.S. Application 10/772,437
Page 3

56. (previously presented) The method according to claim 55, wherein the antibody is administered by an inhalation device.

57. (previously presented) The method according to claim 56, wherein the antibody is administered by a metered dose inhaler.

58. (previously presented) The method according to claim 56, wherein the antibody is administered by a dry powder inhaler.

59. (cancelled)

60. (previously presented) The method according to claim 37, wherein the antibody is administered intravenously.

61. (previously presented) The method according to claim 37, wherein the patient is human.